CureVac's COVID-19 vaccine triggers immune response in Phase I trial
FRANKFURT, Nov 2 (Reuters) - CureVac's experimental COVID-19 vaccine triggered an immune response in humans, it said on Monday, putting the German biotech company on track to start mass testing this year as the race to end the pandemic heats up."W...
